Current Edition

cancer

Novartis aims to keep canakinumab’s early lung cancer hopes alive despite metastatic failure

When Novartis failed in an attempt to repurpose Ilaris for metastatic non-small cell lung cancer (NSCLC), the Swiss pharma played up signs that it said …

Continue Reading →
cancer

In major shake-up, Novartis combines pharma, oncology units, leaving cancer commercial head, CMO out of job

Novartis CEO Vas Narasimhan is giving the Swiss pharma a huge makeover even ahead of a possible spinoff of generics unit Sandoz, pushing out three …

Continue Reading →
copycat

Novo Nordisk and Novartis put Victoza patent suit to bed, teeing up Sandoz copycat by 2024

After Teva Pharmaceutical snagged the OK to launch its Victoza generic in 2023, another copycat has secured a launch timeline for its generic to Novo …

Continue Reading →
Merck

As Russian invasion persists, Roche, Teva, Novartis, Merck and more make renewed push to support besieged Ukraine

As Ukraine holds the line against the Russian invasion, pharma majors are making a renewed push to adjust operations in the region and supply the …

Continue Reading →
AbbVie

AbbVie, Eli Lilly, Novartis and more cut back in Russia amid corporate exodus over Ukraine war

Since the invasion of Ukraine, hundreds of companies have announced a pause or withdrawal of businesses in Russia. Drugmakers Eli Lilly, Novartis and AbbVie are …

Continue Reading →
Blackstone

Novartis’ Sandoz reportedly the target of $25B buyout bid from Carlyle and Blackstone

As Novartis reviews its generics business, the list of potential Sandoz suitors has grown. The deal could become one of the biggest generic industry acquisitions …

Continue Reading →
Amgen

Novartis, Amgen settle their dueling lawsuits over migraine drug Aimovig

Novartis and Amgen have spent years arm wrestling one another over their development and commercialization deal on migraine prevention drug Aimovig. Now, the parties appear …

Continue Reading →
ASH 2021

ASH: Novartis thinks it knows why Kymriah failed in earlier lymphoma but shifts focus to next-gen CAR-T meds

Kymriah’s shocking failure in earlier lymphoma treatment has raised doubts about the Novartis drug’s potency in light of impressive victories from rival CAR-Ts by Gilead …

Continue Reading →
Amgen

For pharmas dealing with HCPs, the future is digital first—and sales reps 2nd

While many people are suffering from Zoom fatigue and looking forward to in-person meetups, that isn’t really the case when it comes to HCPs and …

Continue Reading →
divestment

Novartis CEO Narashimhan confirms interest in purchase of generics unit Sandoz

Amid Novartis’ strategic review of generics unit Sandoz, last month came word that Swedish investment group EQT and the Struengmann brothers of Germany were considering …

Continue Reading →